

## Special Issue

# mTOR Signaling in Disease and Therapy

### Message from the Guest Editors

The mammalian target of rapamycin (mTOR) signaling is an indispensable kinase cascade which regulates the development and homeostasis of mammalian tissues through multiple biological mechanisms. In this regard, as the dysregulation of mTOR signaling is implicated in the pathogenesis of many human diseases, targeting mTOR signaling is a unique therapeutic approach for disease management. We are pleased to invite you to submit your work on mTOR-mediated pathogenesis and the mechanisms of diseases, translational medical research targeting mTOR signaling, and drug discovery based on mTOR cascades. This Special Issue invites basic, preclinical, and translational advances in the diagnosis and treatment of mTOR-related disorders. Original research articles, reviews, and case reports illustrating unique clinical care within the scope of mTOR signaling are welcome. Research areas of interest include, but are not limited to, the following: bone metabolism, craniofacial and oral disorders, stem cells, novel targets in various therapeutic areas, cell/gene/target therapy, and oncology.

- mTOR signaling
- tissue engineering
- stem cell
- disease
- therapy
- biomedicine

---

### Guest Editors

Dr. Wenjing Yu

Department of Orthodontics, University of Pennsylvania School of Dental Medicine, Philadelphia, PA 19104, USA

Dr. Chider Chen

Department of Oral and Maxillofacial Surgery/Pharmacology, University of Pennsylvania School of Dental Medicine, Philadelphia, PA, USA

---

### Deadline for manuscript submissions

31 January 2025



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/194921](https://mdpi.com/si/194921)

*Biomedicines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).